SBI Securities
GTBP icon

SBI Securities’s GT Biopharma GTBP Stock Holding History

SBI Securities’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Hold
0
– – – 4169
2026
Q2 		– Hold
0
– – – 4130
2026
Q1 		– Hold
0
– – – 4084
2025
Q4 		– Hold
0
– – – 3997
2025
Q3 		– Hold
0
– – – 4132
2025
Q2 		– Hold
0
– – – 3908
2025
Q1 		– Sell
-1
Closed -$59 – 3886
2024
Q4 		$49 Buy
+1
New +$68 ﹤0.01% 3648

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Main Street Group
Main Street Group Glen Allen, Virginia $445M AUM 22.95% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

SBI Securities's GTBP Position: Q3 2026 in Review

SBI Securities held its GT Biopharma (GTBP) position steady in Q3 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4169.

SBI Securities first reported a position in GTBP in Q4 2024 and has held it in 1 quarter since. The position peaked at $49 in Q4 2024. 20 funds tracked by Wall St. Rank hold GTBP as of Q3 2026.

  • SBI Securities held 0 shares of GT Biopharma worth $0 as of Q3 2026.
  • SBI Securities left its GT Biopharma share count unchanged in Q3 2026.
  • GT Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #4169 holding.
  • SBI Securities first reported a position in GT Biopharma in Q4 2024 and has held it in 1 quarter since.
  • SBI Securities's GT Biopharma position peaked at $49 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.